What is FibroBiologics, Inc. (FBLG) stock price today?

FibroBiologics, Inc. (FBLG) is currently trading at $1.13, up 1.8% today.

What is FBLG P/E ratio?

FibroBiologics, Inc.'s P/E ratio is -0.20. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is FBLG return on equity (ROE)?

FibroBiologics, Inc.'s return on equity (ROE) is -536.78%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is FibroBiologics, Inc.'s market cap?

FibroBiologics, Inc. has a market capitalization of $2.37M.

NASDAQ · Biotechnology

FibroBiologics, Inc. (FBLG) Stock

$1.13 +1.80% NASDAQ: FBLG Healthcare

Valuation

Metric	Value
Price	$1.13
Market Cap	$2.37M
P/E Ratio	-0.20
P/B Ratio	0.96
P/S Ratio	0.00
EPS (TTM)	$-3.83
52-Week High	$11.40
52-Week Low	$0.62
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-536.78%
ROA	-228.77%
ROCE	-292.67%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.32
Current Ratio	3.00

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-2.0M	$-4.0M	$-9.0M	$-14.0M	$-17.0M
Net Profit	$-2.0M	$-5.0M	$-16.0M	$-11.0M	$-19.0M
EPS	$-0.97	$-3.20	$-11.80	$-6.80	$-8.35
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$0	$5.0M	$12.0M	$16.0M	$10.0M
Total Liabilities	$2.0M	$9.0M	$11.0M	$14.0M	$3.0M
Cash	$0	$2.0M	$9.0M	$14.0M	$5.0M
Borrowings	$1.0M	$8.0M	$2.0M	$11.0M	$2.0M

Latest News

FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors PR Newswire · Jul 9, 2026 FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial PR Newswire · Jul 7, 2026 FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference PR Newswire · Jun 30, 2026 FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules PR Newswire · Jun 29, 2026 FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules PR Newswire · Jun 26, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-1.0M	$-4.0M	$-6.0M	$-12.0M	$-16.0M
Investing Cash Flow	$0	$0	$-1.0M	$0	$-1.0M
Financing Cash Flow	$0	$0	$-3.0M	$0	$0
Net Cash Flow	$0	$2.0M	$7.0M	$5.0M	$-9.0M
Free Cash Flow	$-1.0M	$-4.0M	$-7.0M	$-12.0M	$-17.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.28
EV / EBITDA	-0.02
FCF Yield	-598.24%
Quick Ratio	2.64
Interest Coverage	-77.81
Return 1Y	-93.95%
Return 3Y	—
Return 5Y	—

Ownership

Insiders Held10.81%

Institutions Held10.72%

Institutions Float Held12.02%

Institutional Holder	Shares	Report Date
Vanguard Capital Management LLC	67,665	2026-03-31
Fund Evaluation Group, LLC	51,794	2026-03-31
Geode Capital Management, LLC	29,609	2026-03-31
Blackrock Inc.	24,647	2026-03-31
Cascade Financial Partners, LLC	16,428	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AAPLApple Inc.	$336.64	-1.11%	38.93	$4.94T	0.32%
MSFTMicrosoft Corporation	$535.07	+2.38%	28.68	$3.97T	0.76%
GOOGLAlphabet Inc.	$351.66	+0.97%	16.94	$4.26T	0.26%
AMZNAmazon.com, Inc.	$262.43	+3.29%	19.82	$2.82T	0.00%
METAMeta Platforms, Inc.	$718.67	-0.31%	27.93	$1.83T	0.28%

About FibroBiologics, Inc.

FibroBiologics, Inc. is led by CEO Peter O'Heeron, employs 13 people, headquartered in US, publicly traded since 2024.

FibroBiologics, Inc. (FBLG) stock trades at $1.13 with a market capitalization of $2.37M. The stock is valued at a price-to-earnings (P/E) ratio of -0.20, price-to-book of 0.96, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.62 and $11.40, and currently trades 90.1% below its 52-week high.

On profitability, FibroBiologics, Inc. generates a return on equity (ROE) of -536.78%, return on capital employed of -292.67%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides